

Michael Curry

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8191289/michael-curry-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

66

papers

2,952

citations

22

h-index

54

g-index

73

ext. papers

3,469

ext. citations

7

avg, IF

4.75

L-index

#	Paper	IF	Citations
66	Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. <i>Gastroenterology</i> , 2015 , 149, 649-59	13.3	622
65	Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. <i>New England Journal of Medicine</i> , 2015 , 373, 2618-28	59.2	558
64	Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. <i>Gastroenterology</i> , 2015 , 148, 108-17	13.3	280
63	Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. <i>Gastroenterology</i> , 2015 , 148, 100-107.e1	13.3	266
62	Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 823-831	3.4	80
61	Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection. <i>PLoS ONE</i> , 2016 , 11, e0158431	3.7	74
60	Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study. <i>American Journal of Transplantation</i> , 2013 , 13, 1047-1054	8.7	71
59	Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy For Hepatitis C Virus Infection. <i>Gastroenterology</i> , 2018 , 154, 2111-2121.e8	13.3	70
58	International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. <i>Transplantation</i> , 2017 , 101, 945-955	1.8	63
57	Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 22-27	3.4	62
56	Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 421-430.e6	6.9	62
55	Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. <i>New England Journal of Medicine</i> , 2021 , 384, 818-828	59.2	55
54	Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study. <i>Hepatology</i> , 2016 , 64, 1893-1899	11.2	52
53	Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016 , 1, 122-132	18.8	52
52	Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection. <i>Hepatology</i> , 2017 , 65, 1094-1103	11.2	49
51	Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial. <i>Gastroenterology</i> , 2016 , 151, 893-901.e1	13.3	43
50	Hepatitis B and hepatitis C viruses in liver transplantation. <i>Transplantation</i> , 2004 , 78, 955-63	1.8	38

49	Most ApoL1 Is Secreted by the Liver. <i>Journal of the American Society of Nephrology: JASN</i> , 2017 , 28, 1079-1083	34
48	Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 540-548	6.1 29
47	Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1511-1522	6.1 23
46	Use of growth factors with antiviral therapy for chronic hepatitis C. <i>Clinics in Liver Disease</i> , 2005 , 9, 439-51, vii	4.6 23
45	Neurologic Manifestations of Hepatitis C Virus Infection. <i>Clinics in Liver Disease</i> , 2017 , 21, 535-542	4.6 22
44	Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis. <i>Journal of Hepatology</i> , 2020 , 72, 1112-1121	13.4 22
43	Model for End-Stage Liver Disease score predicts mortality in critically ill cirrhotic patients. <i>Journal of Critical Care</i> , 2014 , 29, 881.e7-13	4 22
42	The gallbladder and biliary tract in cystic fibrosis. <i>Current Gastroenterology Reports</i> , 2005 , 7, 147-53	5 18
41	Performance of an Optimized Paper-Based Test for Rapid Visual Measurement of Alanine Aminotransferase (ALT) in Fingerstick and Venipuncture Samples. <i>PLoS ONE</i> , 2015 , 10, e0128118	3.7 17
40	The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness Analysis. <i>Transplantation</i> , 2017 , 101, 987-995	1.8 16
39	Sofosbuvir and Ribavirin Liver Pharmacokinetics in Patients Infected with Hepatitis C Virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9 16
38	HIV and hepatitis C virus: special concerns for patients with cirrhosis. <i>Journal of Infectious Diseases</i> , 2013 , 207 Suppl 1, S40-4	7 16
37	Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 559-565	18.8 15
36	Early Peribiliary Hyperenhancement on MRI in Patients with Primary Sclerosing Cholangitis: Significance and Association with the Mayo Risk Score. <i>Abdominal Radiology</i> , 2017 , 42, 152-158	3 15
35	Hepatitis C Virus RNA Persists in Liver Explants of Most Patients Awaiting Liver Transplantation Treated With an Interferon-Free Regimen. <i>Gastroenterology</i> , 2016 , 151, 633-636.e3	13.3 15
34	The current knowledge about the therapeutic use of endoscopic sclerotherapy and endoscopic tissue adhesives in variceal bleeding. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019 , 13, 893-897	4.2 14
33	Before or After Transplantation? A Review of the Cost Effectiveness of Treating Waitlisted Patients With Hepatitis C. <i>Transplantation</i> , 2017 , 101, 933-937	1.8 13
32	Primary Stent Placement for Hepatic Artery Stenosis After Liver Transplantation: Improving Primary Patency and Reintervention Rates. <i>Liver Transplantation</i> , 2018 , 24, 1377-1383	4.5 13

31	Macrophage migration inhibitory factor as a novel biomarker of portopulmonary hypertension. <i>Pulmonary Circulation</i> , 2016 , 6, 498-507	2.7	12
30	Fresh frozen plasma transfusion in acute variceal haemorrhage: Results from a multicentre cohort study. <i>Liver International</i> , 2021 , 41, 1901-1908	7.9	12
29	Prevention of allograft HCV recurrence with peri-transplant human monoclonal antibody MBL-HCV1 combined with a single oral direct-acting antiviral: A proof-of-concept study. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 197-206	3.4	10
28	Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection. <i>Advances in Therapy</i> , 2020 , 37, 2267-2274	4.1	10
27	Suboptimal Implementation of Evidence-based Therapy for Acute Variceal Hemorrhage: A Systematic Review of Observational Studies. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 1373-1381.e7	6.9	8
26	Cytokine balance is restored as patient-reported outcomes improve in patients recovering from chronic hepatitis C. <i>Liver International</i> , 2019 , 39, 1631-1640	7.9	7
25	Low yield and utilization of confirmatory testing in a cohort of patients with liver disease assessed for alpha-1 antitrypsin deficiency. <i>Digestive Diseases and Sciences</i> , 2015 , 60, 1589-94	4	6
24	Relationships among neurotransmitters, cytokines and cognitive performance for individuals with hepatitis C achieving sustained virologic response: A pilot study. <i>Journal of Neuroimmunology</i> , 2019 , 335, 577022	3.5	5
23	Cardiovascular Risk Assessment in Renal and Liver Transplant Candidates: A Multidisciplinary Institutional Standardized Approach. <i>Cardiology in Review</i> , 2019 , 27, 286-292	3.2	5
22	Evidence of bias during liver transplant evaluation of non-alcoholic steatohepatitis cirrhosis patients. <i>Liver International</i> , 2019 , 39, 1165-1173	7.9	4
21	Hospital-level balloon tamponade use is associated with increased mortality for all patients presenting with acute variceal haemorrhage. <i>Liver International</i> , 2018 , 38, 477-483	7.9	4
20	Multicenter, Double-Blind, Randomized Trial of Emricasan in Hepatitis C-Treated Liver Transplant Recipients With Residual Fibrosis or Cirrhosis. <i>Liver Transplantation</i> , 2021 , 27, 568-579	4.5	3
19	COVID-19 mRNA Vaccine Immunogenicity in Immunosuppressed Individuals. <i>Journal of Infectious Diseases</i> , 2021 ,	7	2
18	Impact of EGF, IL28B, and PNPLA3 polymorphisms on the outcome of allograft hepatitis C: a multicenter study. <i>Clinical Transplantation</i> , 2016 , 30, 452-60	3.8	2
17	Neoadjuvant Yttrium-90 Transarterial Radioembolization with Resin Microspheres Prescribed Using the Medical Internal Radiation Dose Model for Intrahepatic Cholangiocarcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2021 , 32, 1560-1568	2.4	2
16	Reduced steatosis and weight as a result of specific diets or the dietitian themselves. <i>JHEP Reports</i> , 2021 , 3, 100365	10.3	2
15	Real-world effectiveness of 8-week glecaprevir/pibrentasvir (G/P) for treatment naive, noncirrhotic patients with HCV infection in the TRIO network. <i>GastroHep</i> , 2020 , 2, 64-71	1	1
14	Systematic investigation of elevated transaminases during the third posttransplant month. <i>Liver Transplantation</i> , 2013 , 19 Suppl 2, S17-22	4.5	1

13	Laboratory Tests, Noninvasive Markers of Fibrosis, Liver Biopsy, and Laparoscopy 2017 , 17-37		1
12	Introduction of a Standardized Protocol for Cardiac Risk Assessment in Candidates for Liver Transplant - A Retrospective Cohort Analysis. <i>Annals of Hepatology</i> , 2021 , 100582	3.1	1
11	Lipoprotein Z, a hepatotoxic lipoprotein, predicts outcome in alcohol-associated hepatitis. <i>Hepatology</i> , 2021 ,	11.2	1
10	Comparison of transient elastography and Model for End-Stage Liver Disease-sodium to Model for End-Stage Liver Disease-sodium alone to predict mortality and liver transplantation. <i>European Journal of Gastroenterology and Hepatology</i> , 2021 ,	2.2	1
9	Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational study. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021 , 27, 1239-1248	1.9	1
8	Budd-Chiari Syndrome in a Patient With Simultaneous Diagnosis of Hepatic Sarcoidosis and Nodular Regenerative Hyperplasia. <i>ACG Case Reports Journal</i> , 2019 , 6, e00200	0.6	0
7	The presence of diabetes impacts liver fibrosis and steatosis by transient elastography in a primary care population. <i>Annals of Hepatology</i> , 2021 , 24, 100336	3.1	0
6	Liver biopsy in chronic viral hepatitis: is there still life left in it? 2020 , 9-14		
5	Abdominal Mass Found in a Liver Transplant Recipient. <i>American Journal of Transplantation</i> , 2015 , 15, 2522-4	8.7	
4	Pulmonary Vessel Cross-sectional Area before and after Liver Transplantation: Quantification with Computed Tomography. <i>Academic Radiology</i> , 2015 , 22, 752-9	4.3	
3	Prophylaxis against recurrent hepatitis B virus infection after liver transplantation. <i>Current Hepatitis Reports</i> , 2007 , 6, 30-34		
2	Posttransplant Lymphoproliferative Disorder Isolated to the Adrenal Gland in a Liver Transplant Patient. <i>ACG Case Reports Journal</i> , 2018 , 5, e10	0.6	
1	Reply to: The presence of diabetes impacts liver fibrosis and steatosis by transient elastography in a primary care population. <i>Annals of Hepatology</i> , 2021 , 25, 100347	3.1	